MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Medtech in a Minute: Stryker, Glaukos, and Elizabeth Holmes

Graphic by Amanda Pedersen / MD+DI Medtech news
It was a busy news week in medtech. Here's what you need to know to bring you up to speed quickly.

Stryker Hops Back on the M&A Train

Stryker acquired Gauss Surgical, developer of an AI-enabled platform for real-time monitoring of blood loss during surgery. The technology, Triton, has demonstrated improvements in maternal and surgical care through earlier recognition of hemorrhage leading to earlier intervention. The deal comes almost a year after Stryker closed on Wright Medical — one of its biggest acquisitions in recent history. In July, Stryker CEO Kevin Lobo mentioned that the company would be looking for tuck-in merger and aquisition (M&A) deals in the future.

Jury Tasked with Figuring Out Who Elizabeth Holmes Really Is

Is Elizabeth Holmes a hardworking executive manipulated by her ex-boyfriend and former chief operating officer, or is she a fraudster who pulled the wool over everyone's eyes? A 17-member jury heard two very different takes on Holmes during the opening statements of the former Theranos CEO's fraud trial.

Glaukos Seeks Approval for iStent Infinite

Glaukos is one step closer to bringing a new minimally invasive glaucoma surgery to the U.S. market. The company has submitted a supplemental PMA application to FDA for the iStent infiniteTrabecular Micro-Bypass System. The device is designed to reduce elevated intraocular pressure in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy.

And in case you missed our last Medtech in a Minute report...

Jury Selection Gets Underway in Holmes' Trial

Elizabeth Holmes is back in the mainstream news headlines this week as jury selection begins for her fraud trial. Opening statements are expected Sept. 8. The trial signals the beginning of the end of the industry's biggest scandal in recent history. Don't expect it to be a fast trial though, experts say it could take three months. Click the headline above for the full story. Or, for a quick visual of how Theranos' valuation skyrocketed and then plummeted, check out this graphic by News Editor Amanda Pedersen.

Rumor confirmed: Baxter to Acquire Hillrom for $12.4 billion

After weeks of speculation, Baxter confirmed this week that it has agreed to acquire Hillrom in a deal valued at $12.4 billion. The merger has the potential to expand access to Hillrom’s portfolio globally; broaden the presence of the combined companies across sites of care and accelerate and strengthen the combined organization’s digital transformation.

Zimmer Biomet Is Making Knees Smarter

FDA cleared Zimmer Biomet's Persona IQ smart knee implant, making it the first "smart" knee implant on the market for total knee replacement surgery. The device was previously identified by MD+DI as one of the 10 Most Anticipated New Medical Devices expected to reach the U.S. market by the end of the year.

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish